NCT00027092: Testosterone and metabolism in men with HIV

Medicine Signal Editorial Desk
Updated 2026-10-10

Registry status when checked 2026-10-10Completed

NCT00027092 was a metabolic substudy in men with HIV, visceral obesity, and low testosterone. The NIAID record identifies A5112s, associated with parent study A5079, rather than a general diabetes-treatment trial. 1 2

The parent research compared testosterone gel with placebo. This observational substudy added detailed insulin/glucose testing, including frequently sampled intravenous glucose-tolerance assessments at baseline and approximately weeks 24 and 48. The enrollment field lists 50, without enough detail here to substitute that for a verified analysis sample; the historical record is completed. 1 2

The central question was how testosterone-related treatment and body composition related to insulin sensitivity. Numerical metabolic effects were not verified. The record does not justify testosterone treatment for everyone with HIV, nor does it concern eradication of HIV. 1 2

Sources

1. ClinicalTrials.gov — ClinicalTrials.gov — NCT00027092. Original study registration: sponsor, design, population, endpoints and dated history.Original study registration · Original record checked against the registry API. Checked 2026-10-10. Registration and current registry fields do not by themselves establish efficacy. Historical details in the article retain their stated date. Supplied note: ClinicalTrials.gov — NCT00027092. Original study registration: sponsor, design, population, endpoints and dated history.

2. ICH GCP — ICH GCP — readable reproduction of the sponsor-submitted ClinicalTrials.gov record. Supports the registration details quoted here; not an independent clinical-results publication.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.